GENESIS GOMEZ: Open Payments
NPI 1104488907 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,138 in 57 payments from 14 companies in 2025. Trend: 2023 $710 · 2024 $730 · 2025 $1,138
Food & beverage: $1,138
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $389 |
| Phathom Pharmaceuticals, Inc. | 5 | $154 |
| Madrigal Pharmaceuticals | 4 | $122 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $77 |
| VIVUS LLC | 4 | $63 |
| Ardelyx, Inc. | 3 | $53 |
| Gilead Sciences, Inc. | 2 | $48 |
| GENZYME CORPORATION | 2 | $34 |
| Novo Nordisk Inc | 1 | $20 |
Products named: CREON, VOQUEZNA, MAVYRET, REZDIFFRA, XIFAXAN, LINZESS, PANCREAZE, IBSRELA.
Industry payments across NY — which companies pay providers there.
